Phaseline

Companies › Revolution Medicines

Revolution Medicines: clinical trials, targets and expected readouts

8 active drug programs in 49 registered trials: 22 Phase 1, 19 Phase 2, 8 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RMC-6236
RAS(ON) inhibitor - KRAS G12C inhibitor
KRASPhase 3Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal CancerDec 2026
Daraxonrasib
KRAS(ON) inhibitor
KRASPhase 3NSCLC (Non-small Cell Lung Cancer); Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC) …Dec 2027
Zoldonrasib
KRAS(ON) inhibitor
KRASPhase 3Pancreatic Cancer; NSCLC; Advanced Solid TumorsDec 2028
RMC-9805
RAS(ON) inhibitor - KRAS inhibitor
KRASPhase 1Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal CancerDec 2026
RMC-6291
KRAS(ON) inhibitor
KRASPhase 1Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLCMar 2027
RMC-5127
KRAS G12V inhibitor
–Phase 1Non-small Cell Lung Cancer (NSCLC)Apr 2028
Elironrasib
KRAS(ON) inhibitor
KRASPhase 1Non-Small Cell Lung Cancer (NSCLC); Advanced Solid TumorsDec 2028
Ivonescimab
PD-1 and CTLA-4 dual antagonist
PD-1, CTLA4Phase 1Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma …May 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07070466IvonescimabPhase 2Stomach Cancer Stage IVOncologyDec 2026
NCT06769971IvonescimabPhase 2Small Cell Lung CancerOncologyDec 2026
NCT06040541RMC-6236Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyDec 2026
NCT06040541RMC-9805Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyDec 2026
NCT07070479IvonescimabPhase 2Recurrent or Metastatic Nasopharyngeal CarcinomaOncologyJan 2027
NCT07162714IvonescimabPhase 2Rectal CancerOncologyMar 2027
NCT05462717RMC-6291Phase 1Non-Small Cell Lung Cancer (NSCLC)OncologyMar 2027
NCT06925724IvonescimabPhase 2Endometrial CancerOncologyApr 2027
NCT07655570IvonescimabPhase 2Cutaneous AngiosarcomaOncologyMay 2027
NCT05379985RMC-6236Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyMay 2027
NCT06162221RMC-6236Phase 1Non-Small Cell Lung Cancer, NSCLCOncologyJun 2027
NCT06162221RMC-9805Phase 1Non-Small Cell Lung Cancer, NSCLCOncologyJun 2027
NCT06162221RMC-6291Phase 1Non-Small Cell Lung Cancer, NSCLCOncologyJun 2027
NCT06491472IvonescimabPhase 2Pancreatic CancerOncologyJul 2027
NCT06529718IvonescimabPhase 2Biliary Tract CancerOncologyAug 2027
NCT07229417IvonescimabPhase 2Metastatic Endocrine RefractoryOncologySep 2027
NCT06881784DaraxonrasibPhase 3NSCLC (Non-small Cell Lung Cancer)OncologyDec 2027
NCT07017673IvonescimabPhase 2TNBCOncologyDec 2027
NCT06625320RMC-6236Phase 3Pancreatic CancerOncologyDec 2027
NCT07472478IvonescimabPhase 2Lung Cancer (NSCLC)OncologyDec 2027
NCT06875076IvonescimabPhase 2Pretreated Pleural MesotheliomaOncologyJan 2028
NCT06940518IvonescimabPhase 2IvonescimabOncologyJan 2028
NCT06672575IvonescimabPhase 1GlioblastomaOncologyJan 2028
NCT06840834IvonescimabPhase 2Pleural MesotheliomasOncologyMar 2028
NCT07349537DaraxonrasibPhase 1Non-small Cell Lung Cancer (NSCLC)OncologyApr 2028
NCT07535463IvonescimabPhase 1Non-Small Cell Lung CancerOncologyApr 2028
NCT07535437IvonescimabPhase 1Non-Small Cell Lung CancerOncologyApr 2028
NCT07349537RMC-5127Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyApr 2028
NCT07594522IvonescimabPhase 1Non-Small Cell Lung CancerOncologyMay 2028
NCT07076693IvonescimabPhase 2OligoProgressive Metastatic DiseaseOncologyMay 2028
NCT07491445DaraxonrasibPhase 3Pancreatic CancerOncologyJun 2028
NCT06959550IvonescimabPhase 2Metastatic Colorectal CancerOncologyJul 2028
NCT06951646IvonescimabPhase 2Non Small Cell Lung CancerOncologyJul 2028
NCT06567314IvonescimabPhase 2Cutaneous Squamous Cell CarcinomaOncologySep 2028
NCT06445062RMC-6236Phase 1Colorectal CancerOncologySep 2028
NCT06445062RMC-9805Phase 1Colorectal CancerOncologySep 2028
NCT06128551DaraxonrasibPhase 1Non-Small Cell Lung Cancer (NSCLC)OncologyDec 2028
NCT06128551ElironrasibPhase 1Non-Small Cell Lung Cancer (NSCLC)OncologyDec 2028
NCT07621718ZoldonrasibPhase 3Pancreatic CancerOncologyDec 2028
NCT07805954DaraxonrasibPhase 3Pancreatic CancerOncologyMar 2029
NCT07805954ZoldonrasibPhase 3Pancreatic CancerOncologyMar 2029
NCT07516925IvonescimabPhase 2LeiomyosarcomaOncologyApr 2029
NCT07252232DaraxonrasibPhase 3Pancreatic CancerOncologyMay 2029
NCT07397338DaraxonrasibPhase 1Advanced Solid TumorsOncologyMay 2029
NCT07397338ElironrasibPhase 1Advanced Solid TumorsOncologyMay 2029
NCT07397338ZoldonrasibPhase 1Advanced Solid TumorsOncologyMay 2029
NCT07397338IvonescimabPhase 1Advanced Solid TumorsOncologyMay 2029
NCT07619339IvonescimabPhase 1Non-Small Cell Lung CancerOncologyMay 2029
NCT07777822ZoldonrasibPhase 3NSCLCOncologyOct 2029

From the company's SEC filings

Cash and short-term investments of $3.7bn on 2026-09-30; operating cash outflow about $1.6bn a year; runway about 28 months at that burn, to Feb 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 19 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KRAS (6) PD-1 (1) CTLA4 (1)

Companies with the same targets

Bristol-Myers Squibb TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Amgen Novartis Astellas Abbisko Therapeutics Ranok Therapeutics (Hangzhou)

Companies built like this

BicycleTx Erasca IDEAYA Biosciences Kumquat Biosciences Vividion Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.